TICKERNERD
Menu
RXRXRXRXHealthcare · Biotechnology

RXRX Stock Forecast: Recursion Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$3.16
−4.53% on the day

The 7 Wall Street analysts covering Recursion Pharmaceuticals, Inc. hold a median 12-month price target of $7 — +121.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 15 Aug 2026 — in the lower half.

Market cap
$1.7B
Ticker Nerd rank
43 / 100
Median analyst target
$7.00
Analysts covering
7
Total return, dividends reinvested
1W
−1.9%
1M
−5.4%
YTD
−22.7%
1Y
−44.0%
From 52W high
−53.5%
From 52W low
+11.3%
$2.84
$6.79
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RXRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Recursion Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
85
Accruals
82
Revisions
63
Issuance
50
Quality
39
Size
39
Volatility
32
Value
26
Momentum
14

Growth (85): Sales and profits are climbing, and climbing faster than before.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RXRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RXRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26RXRXHigh $10.00Median $7.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
3 Buy4 Hold0 Sell
Low $4.00Median $7.00High $10.00

The green dot is the last close — the median target sits +121.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 May 2026Morgan StanleyMaintainsEqual-Weight$5.00 → $5.50
7 May 2026NeedhamReiteratesBuy$8.00
30 Apr 2026JP MorganMaintainsOverweight—
26 Feb 2026B of A SecuritiesMaintainsNeutral—
26 Feb 2026NeedhamReiteratesBuy—
17 Dec 2025JP MorganUpgradeOverweight—
11 Sept 2025NeedhamReiteratesBuy—
8 July 2025NeedhamReiteratesBuy—
3 July 2025Morgan StanleyAssumesEqual-Weight$5.00
16 June 2025Morgan StanleyMaintainsEqual-Weight—
6 May 2025NeedhamMaintainsBuy—
10 Apr 2025Morgan StanleyMaintainsEqual-Weight—
8 Apr 2025NeedhamReiteratesBuy—
28 Feb 2025Leerink PartnersMaintainsMarket Perform—
6 Feb 2025NeedhamReiteratesBuy—
8 Jan 2025KeybancMaintainsOverweight—
11 Dec 2024NeedhamReiteratesBuy—
20 Nov 2024NeedhamReiteratesBuy—
7 Nov 2024NeedhamReiteratesBuy—
4 Sept 2024NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RXRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RXRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Recursion Pharmaceuticals, Inc. (RXRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.2×

Cheaper than 85% of US stocks

Price / sales
30.9×

Cheaper than 7% of US stocks

Price / book
1.8×

Cheaper than 49% of US stocks

EV / EBITDA
−2.6×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
−60.1%

Higher than 4% of US stocks

Earnings growth (YoY)
−61.8%

Higher than 8% of US stocks

Gross margin
−57.3%

Higher than 2% of US stocks

Operating margin
−1759.7%

Higher than 4% of US stocks

Net margin
4.4%

Higher than 58% of US stocks

Returns & dividend
Return on equity
−56.6%

Higher than 20% of US stocks

Return on assets
−27.3%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RXRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RXRXRecursion Pharmaceuticals, Inc.$1.7B
43
FTREFortrea Holdings, Inc.$1.6B
97
NTLAIntellia Therapeutics, Inc.$1.7B
53
XNCRXencor, Inc.$1.7B
82
FBRXForte Biosciences, Inc.$1.6B
35
BCAXBicara Therapeutics, Inc.$1.6B
48
INVAInnoviva, Inc.$1.6B
85

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Recursion Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RXRX news & analysis

Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates

MarketBeat · 17 Aug 2026neutral

Recursion Pharmaceuticals' CFO and President of Recursion U.K., Ben Taylor, discussed the company's use of artificial intelligence to generate and analyze biological data during a BofA Global Research virtual conference. He highlighted how the AI platform aims to improve drug discovery, advance internal therapeutic programs, and support collaborations with larger pharmaceutical companies, while also covering pipeline updates and progress with Roche.

Why it matters — RXRX watchers would care because the presentation details how Recursion's AI-driven approach supports its drug discovery efforts and its collaboration with Roche, offering insight into the company's strategy and pipeline direction.

Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News

Seeking Alpha · 10 Aug 2026negative

Recursion Pharmaceuticals is described as remaining a Hold, with competitive advances and slow revenue growth challenging its AI-driven drug discovery ambitions. Despite $500M+ in milestone payments from partnerships with Genentech/Roche and Sanofi, further commercial validation is pending, and its internal lead candidate REC-4881 may lag competitors and is unlikely to generate significant revenue before 2030.

Why it matters — A RXRX watcher would care because the item highlights doubts about the company's internal pipeline competitiveness and the timing of meaningful commercial revenue.

RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down

Zacks Investment Research · 6 Aug 2026negative

Recursion Pharmaceuticals reported Q2 results that missed earnings and revenue estimates, with collaboration revenues declining year over year, causing the stock to fall. Meanwhile, pipeline and partnership programs continued to advance.

Why it matters — RXRX watchers would care because the quarterly miss and falling collaboration revenue weighed on the stock even as the company's pipeline and partnerships progressed.``

Recursion Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026neutral

Recursion Pharmaceuticals' Q2 earnings call highlighted progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform. The company lowered its 2026 cash operating expense guidance to $375 million and reaffirmed expectations for an operating runway through early 2028.

Why it matters — RXRX watchers would care because the reduced cash expense guidance and reaffirmed runway through early 2028 give a clearer picture of the company's financial sustainability as it advances its pipeline.

FAQ

Frequently asked questions about RXRX stock

What is the RXRX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Recursion Pharmaceuticals, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RXRX stock a buy right now?

Of the 7 analysts covering Recursion Pharmaceuticals, Inc., 3 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Recursion Pharmaceuticals, Inc. 43 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RXRX?

As at 15 Aug 2026, Recursion Pharmaceuticals, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).

Will RXRX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +121.5% from the last close, and Ticker Nerd's factor model ranks Recursion Pharmaceuticals, Inc. 43 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RXRX stock forecast for 2030?

No analyst covering Recursion Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RXRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has RXRX stock performed over the past year?

Recursion Pharmaceuticals, Inc. returned -44.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Recursion Pharmaceuticals, Inc. do?

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on using automation, artificial intelligence, machine learning, and data science to discover novel medicines.

What is the latest news on RXRX?

The most recent item we track (MarketBeat, 17 Aug 2026): "Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates". Recursion Pharmaceuticals' CFO and President of Recursion U.K., Ben Taylor, discussed the company's use of artificial intelligence to generate and analyze biological data during a BofA Global Research virtual conference. He highlighted how the AI platform aims to improve drug discovery, advance internal therapeutic programs, and support collaborations with larger pharmaceutical companies, while also covering pipeline updates and progress with Roche.

Company

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on using automation, artificial intelligence, machine learning, and data science to discover novel medicines. Recursion Pharmaceuticals develops a technology-driven drug discovery platform that combines biology, chemistry, engineering, and computational tools to identify potential drug candidates, study mechanisms of action, and evaluate safety signals. Its work centers on industrializing the process of discovering therapeutics for serious diseases, with programs that span multiple research areas within the life sciences. The company operates as a biotechnology platform business, supporting both internal drug development and broader scientific applications through its integrated Recursion operating system. Headquartered in Salt Lake City, Utah, and founded in 2013, Recursion Pharmaceuticals plays a distinctive role in the market by merging advanced computing with experimental biology to accelerate modern drug discovery.

CEO Dr. Najat Khan Ph.D. · 600 employees · United States · https://www.recursion.com